These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

841 related items for PubMed ID: 19165529

  • 1. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Rösler M, Fischer R, Ammer R, Ose C, Retz W.
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
    [Abstract] [Full Text] [Related]

  • 2. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
    Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, Fischer R, Ammer R, Study Group.
    World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
    [Abstract] [Full Text] [Related]

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 4. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.
    Biol Psychiatry; 2006 May 01; 59(9):829-35. PubMed ID: 16373066
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ, COMACS Study Group.
    Pediatrics; 2004 Mar 01; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [Abstract] [Full Text] [Related]

  • 10. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM.
    J Clin Psychiatry; 2010 Dec 01; 71(12):1680-8. PubMed ID: 20492837
    [Abstract] [Full Text] [Related]

  • 11. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.
    López FA, Faraone SV, Newcorn JH, Doll HA, Rhoten S, Lewis HB, Khan TF, DeSousa NJ, Sallee FR, Incledon B.
    J Child Adolesc Psychopharmacol; 2021 Apr 01; 31(3):179-186. PubMed ID: 33797983
    [Abstract] [Full Text] [Related]

  • 12. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS, Yeh CB, Chen CH, Shang CY, Gau SS.
    J Child Adolesc Psychopharmacol; 2021 Apr 01; 31(3):164-178. PubMed ID: 33395356
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.
    J Child Adolesc Psychopharmacol; 2017 Aug 01; 27(6):474-482. PubMed ID: 29172680
    [Abstract] [Full Text] [Related]

  • 14. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
    Huss M, Ginsberg Y, Arngrim T, Philipsen A, Carter K, Chen CW, Gandhi P, Kumar V.
    Clin Drug Investig; 2014 Sep 01; 34(9):639-49. PubMed ID: 25015027
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group.
    Biol Psychiatry; 2007 Jun 15; 61(12):1380-7. PubMed ID: 17137560
    [Abstract] [Full Text] [Related]

  • 16. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.
    Eur Neuropsychopharmacol; 2013 Oct 15; 23(10):1208-18. PubMed ID: 23332456
    [Abstract] [Full Text] [Related]

  • 17. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC, Kollins SH, Foehl HC, Newcorn JH, Mattingly G, Kupper RJ, Adjei AL.
    J Child Adolesc Psychopharmacol; 2020 Mar 15; 30(2):58-68. PubMed ID: 32125903
    [Abstract] [Full Text] [Related]

  • 18. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study.
    Ginsberg Y, Arngrim T, Philipsen A, Gandhi P, Chen CW, Kumar V, Huss M.
    CNS Drugs; 2014 Oct 15; 28(10):951-62. PubMed ID: 25183661
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.